Xianfeng Lu - Concepedia

Author

Xianfeng Lu

Army Medical University

Also Known As

Xian-Feng Lu, Xianfeng LU, Xianfeng Lu

Publications

271

Citations

H-Index

Concepts

All Affiliations

Army Medical University Daping Hospital

About

Xianfeng Lu is an author at Army Medical University specializing in medicine, immunology, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	146
2	Immunology	2	2	79
3	Pathology	2	2	79
4	Cell Biology	1	1	67
5	Molecular Medicine	1	1	67

Xianfeng Lu

Publications

247

Citations

H-Index

Page 1

	Year	Citations
Serum APE1 Autoantibodies: A Novel Potential Tumor Marker and Predictor of Chemotherapeutic Efficacy in Non-Small Cell Lung Cancer Nan Dai, Xiaojing Cao, Mengxia Li, PLoS ONE Tumor BiologySerum Ape1 AutoantibodiesMedicineImmunologySerum Ape1-aabs	2013	67
APE1 deficiency promotes cellular senescence and premature aging features Mengxia Li, Xiao Yang, Xianfeng Lu, Nucleic Acids Research Dna DamageAgingGeneticsApoptosisCell Death	2018	67
The regulatory role of APE1 in epithelial‐to‐mesenchymal transition and in determining EGFR‐TKI responsiveness in non‐small‐cell lung cancer Xiao Yang, Yu Peng, Xuan Jiang, Cancer Medicine	2018	43
Distinct circulating cytokine/chemokine profiles correlate with clinical benefit of immune checkpoint inhibitor monotherapy and combination therapy in advanced non‐small cell lung cancer Yue Hu, Shixun Li, He Xiao, Cancer Medicine	2023	18
Next generation sequencing targeted detection of somatic mutations in patients with mucinous adenocarcinoma of the appendix Dan Jian, Xianfeng Lu, Dong Wang, Annals of Diagnostic Pathology	2022	16
Estimating the prognosis of esophageal squamous cell carcinoma based on The Cancer Genome Atlas (TCGA) of m6A methylation-associated genes Yu Pu, Xianfeng Lu, Xueqin Yang, Journal of Gastrointestinal Oncology	2021	14
Impact of T-cell receptor and B-cell receptor repertoire on the recurrence of early stage lung adenocarcinoma Jie Liu, Xiao Yang, Xianfeng Lu, Experimental Cell Research Cancer ImmunosurveillanceT-regulatory CellImmunologyT-cell ReceptorPathology	2020	12
415 Toripalimab plus nab-paclitaxel and carboplatin as neoadjuvant therapy for patients with esophageal squamous cell carcinoma at clinical stage T2-T4/N0-N2/M0: a single-arm, single-center clinical study Kunkun Li, Xiao Yang, Wei Luo, Regular and Young Investigator Award Abstracts	2020	10

Page 1